Almac has reported that the expansion of its API manufacturing facilities has allowed significant growth in its late stage manufacturing service.

The facility upgrade included installation of two 1,000L reactors and pressure filter dryer, which now allows production of highly potent API manufacture up to 500kg with a dedicated nitrogen jet mill for micronisation.

Denis Geffroy, VP Business Development, commented: “Over the past few years, Almac’s API business has continued to grow at a double digit pace. The facility expansion was much needed and the results are already striking with several Phase III and Commercial projects awarded.”

Almac’s clients also leverage Almac’s API and Drug Product integrated offering where API manufacture and finished drug production is carried out on the same site, ensuring reduction in costs and timelines whilst maintaining scientific continuity.

This year Almac has completed its first joint commercial API and Drug Product manufacture which demonstrated the advantages of integrated operations.

“Today, our API business is made of 30% late phase and commercial projects, compared to just 5% 3 years ago, which gives a clear indication that our strategy to invest through expansion was the right one.” added Denis.

A stunning report concludes that researchers often ask statisticians to make "inappropriate requests." Not accidental requests for incorrect statistical analyses; but unscrupulous data manipulation or even fraud.